**Core Concept:** Malignant Hyperthermia (MH) is a rare but potentially life-threatening complication of general anesthesia in susceptible individuals. It is caused by mutations in the RYR1 or CACNA1S genes, leading to abnormal calcium release from sarcoplasmic reticulum in skeletal muscle fibers.

**Why the Correct Answer is Right:** The correct answer, Dantrolene, is a calcium channel blocker that works by inhibiting the ryanodine receptors (RYR1) involved in the pathogenesis of MH. By blocking these receptors, Dantrolene prevents excessive calcium release from sarcoplasmic reticulum, thereby preventing the hypermetabolic state and muscle rigidity characteristic of MH.

**Why Each Wrong Option is Incorrect:**
A. Halothane and Succinylcholine are the two main anesthetic agents implicated in triggering MH. However, neither is a direct treatment for MH.
B. Dantrolene is the correct treatment, not the incorrect option.
C. Tranexamic acid is an antifibrinolytic agent used to prevent and treat excessive bleeding in certain medical conditions, but it does not treat MH.
D. Pentobarbital is a barbiturate sedative-hypnotic agent used in anesthesia, but it is not the correct treatment for MH.

**Clinical Pearl:** A high index of suspicion for MH is crucial in patients with risk factors like known family history, history of MH, or exposure to anesthetic agents known to trigger MH. Early recognition and administration of Dantrolene can prevent severe complications or even death in MH cases.